Stevanato (STVN) Q3 2026 Earnings Call Transcript

Stevanato Group reported Q3 2026 revenue of EUR 326.1 million, up 8% reported and organically, while adjusted EBITDA rose 14% to EUR 88.8 million and its margin expanded 150 basis points to 27.2%. The company reiterated FY2026 revenue guidance of EUR 1.26 billion–EUR 1.28 billion, but expects low-single-digit growth in 2027 as lower GLP-1-related Nexa syringe volumes from one customer temporarily moderate growth; delayed orders also weigh on the engineering segment. Management said it has backfilled most of the expected capacity shortfall and anticipates a return to high-single-digit to low-double-digit growth in 2028.

Analysis

The key read-through is concentration, not the quarter: one customer’s lower GLP-1 syringe demand also weighs on engineering orders, so the 2027 moderation may reflect a shared customer-cycle shock across two segments rather than an isolated product reset. Management’s “temporary” framing depends on replacement programs clearing validation and converting into revenue on schedule; pipeline activity is not equivalent to binding orders. If that timing slips, both utilization and the return on heavy capacity investment weaken.

The offset is a potentially better mix of customers and products, but it is not yet fully evidenced in reported HVS growth. Non-GLP biologics strength and RTU adoption support the structural case; Annex 1 is a gradual conversion catalyst, not a near-term guarantee. West Pharmaceutical Services and Gerresheimer are relevant competitive checks for customer allocations and RTU capacity, but the call provides no evidence of share shifts.

Near term, the engineering order-conversion problem and European utility-cost repricing lag can constrain margins even if BDS demand holds. Over 6–18 months, the test is whether Fishers utilization, new device launches, and validated replacement syringe programs convert capex into cash returns. Net debt and substantial planned investment make execution and free cash flow more important than the growth narrative alone. The market may be underweighting this conversion risk while focusing on the longer-term biologics pipeline; there is insufficient information here to conclude valuation is mispriced.

Key Decisions for Investors

• Avoid chasing STVN solely on the 2028 growth narrative. Treat the shares as a watch/accumulate-on-weakness candidate only if upcoming updates show replacement Nexa volumes moving from validation into orders and 2027 growth guidance remains intact.
• For the next 1–3 months, monitor binding customer forecasts, engineering signed orders, HVS mix, and free cash flow versus capex. A further engineering guidance cut or weaker-than-expected backfill would undermine the recovery case; successful order conversion and positive cash generation would improve the setup.
• Keep exposure sized for a customer-concentration downside: the GLP-1 customer affects both BDS and engineering, and contract protections have not been quantified. Reassess if management revises the 2027 outlook below low-single-digit growth or indicates replacement programs are delayed.
• Use West Pharmaceutical Services and Gerresheimer as industry checks—not automatic pair-trade shorts—for evidence on RTU demand, customer qualification pace, and syringe or cartridge allocation. The article does not establish relative valuation or market-share gains needed to support a pair trade.